PMID- 34318966
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 26
IP  - 5
DP  - 2021 Oct
TI  - 10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter 
      pylori: A propensity score matching analysis.
PG  - e12833
LID - 10.1111/hel.12833 [doi]
AB  - BACKGROUND: Inconsistent eradication rates for Helicobacter pylori have been 
      reported worldwide with dual therapy, perhaps owing to the difference in dose 
      administration and treatment duration. This retrospective study aimed to 
      determine whether high-dose dual therapy (HDDT) with different regimens leads to 
      different eradication rates. The study compares the efficacy and safety of HDDT 
      10-day vs 14-day and investigates the factors that might affect the eradication 
      rates. MATERIALS AND METHODS: Two comparable treatment groups were based on 
      propensity score matching (PSM). Patients were divided into two groups based on 
      the therapy they underwent: 10-day HDDT and 14-day HDDT (20 mg esomeprazole and 
      750 mg amoxicillin, administered four times daily). The eradication rates, 
      adverse events (AEs), patient compliance, CYP2C19 gene polymorphisms, and 
      antibiotic resistance rates of the two groups were compared. RESULTS: The 
      intention to treat (ITT) analysis showed that the eradication rates for 10-day 
      and 14-day groups were 78.4% (95% CI 69.6%-87.2%) and 89.7% (95% CI 83.3%-96.2%; 
      p = .039), respectively, while the per-protocol (PP) eradication rates were 80.0% 
      (95% CI 71.3%-88.7%) and 92.9% (95% CI 87.4%-98.5%; p = .014), respectively. The 
      corresponding drug-related AEs were 6.8% (6/88) and 5.7% (5/88; p = .755). No 
      significant differences were observed between the compliance rates of the two 
      groups. The CYP2C19 gene polymorphism had no effect on the eradication rates of 
      the two groups. CONCLUSION: The results showed that the 14-day HDDT affords a 
      higher H. pylori eradication rate than the 10-day HDDT.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Zou, Pei-Ying
AU  - Zou PY
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Hu, Jie
AU  - Hu J
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Zhao, Jing-Tao
AU  - Zhao JT
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Zhao, Zhe
AU  - Zhao Z
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Mei, Hao
AU  - Mei H
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Zhu, Yang-Jie
AU  - Zhu YJ
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Lan, Chun-Hui
AU  - Lan CH
AUID- ORCID: 0000-0002-9232-7910
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University, 
      Chongqing, China.
LA  - eng
GR  - 2018MSXM014/Chongqing Science-Health Joint Medical Research Project Development/
GR  - 20I9CXLCB003/Science and Technology Innovation Enhancement Project of Army 
      Medical University/
PT  - Journal Article
DEP - 20210728
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/adverse effects
MH  - Clarithromycin/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Propensity Score
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - dual therapy
OT  - eradication rate
OT  - propensity score matching
OT  - treatment duration
EDAT- 2021/07/29 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/07/28 08:57
PHST- 2021/06/16 00:00 [revised]
PHST- 2021/02/23 00:00 [received]
PHST- 2021/06/21 00:00 [accepted]
PHST- 2021/07/29 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/07/28 08:57 [entrez]
AID - 10.1111/hel.12833 [doi]
PST - ppublish
SO  - Helicobacter. 2021 Oct;26(5):e12833. doi: 10.1111/hel.12833. Epub 2021 Jul 28.